What does this research mean for the field?

Tirzepatide and semaglutide lead to significant weight loss at 6 months in a subgroup of highly persistent and adherent Medicaid members. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

This research aims to assess the persistence and adherence to GLP-1 medications and their weight loss effectiveness in a Medicaid population over six months.

March 2, 2026

Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population

Key Points

This research aims to assess the persistence and adherence to GLP-1 medications and their weight loss effectiveness in a Medicaid population over six months.
Analyzed MassHealth members' adherence to GLP-1 and GLP-1/GIP treatments over six months.
Measured weight loss outcomes among highly persistent and adherent participants.
Evaluated the effectiveness of tirzepatide and semaglutide in the studied population.
At six months, participants showed moderate persistence and adherence to GLP-1 treatment.
Significant weight loss was observed among members who were highly persistent and adherent.
Tirzepatide and semaglutide were found effective in the weight loss efforts of those participants.

Abstract

At 6 months, MassHealth members showed moderate persistence and adherence to GLP-1 or GLP-1/GIP treatment. Tirzepatide and semaglutide were effective in producing significant weight loss at 6 months among a subgroup of highly persistent and adherent members.

Bookmark

Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population

Key Points

Abstract

Cite This Study